An experienced team when it comes to running preclinical Adoptive Cell Transfer Therapy Studies

TD2 offers a consultative approach for optimal CAR-T study design. With experience in both solid and hematological tumors, our team will design and execute your preclinical program to best support your clinical and regulatory goals.

Cell Therapy Capabilities include:

  • Optical imaging (Bioluminescence and Fluorescence)
  • Orthotopic and surgical
  • IP Dissemination
  • IV Dissemination
  • Hematological
  • Biodistribution
  • Non-GLP Toxicity


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.